Trial Profile
A Randomized, Open-Label, Multi-Arm, Dose Escalation, Phase 1a Trial Assessing the Safety, Tolerability, and Immunogenicity of GI-13020; an Inactivated Recombinant Saccharomyces Cerevisiae Expressing Hepatitis B Virus X, Surface and Core Antigens, at Various Dose Levels and Regimens in Healthy Adults.
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 07 Nov 2021
Price :
$35
*
At a glance
- Drugs GS 4774 (Primary)
- Indications Hepatitis B
- Focus Adverse reactions
- Sponsors Gilead Sciences
- 09 May 2013 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov
- 05 Feb 2013 New trial record